Amphastar Pharmaceuticals, INC Form 4 insider transactions

Richard K Prins, a Director of Amphastar Pharmaceuticals, Inc., sold 7,973 shares of common stock on August 11, 2026 for $20.30 per share.

William J Peters, CFO, EVP & TREASURER and a Director of Amphastar Pharmaceuticals, Inc., sold 8,180 shares of common stock on August 7, 2026 for $22.48 per share.

Anthony T Pierce, a Director of Amphastar Pharmaceuticals, Inc., reported multiple transactions in common stock on July 9, 2026.

Director Richard K. Prins reported a gift of common stock and the acquisition of restricted stock units and options in Amphastar Pharmaceuticals.

Director Howard Lee acquired restricted stock units and stock options while disposing of shares to cover tax obligations.

Director Michael A. Zasloff acquired 8,143 restricted stock units and 17,365 stock options in Amphastar Pharmaceuticals.

Director Diane Gerst acquired 8,143 restricted stock units and 17,365 stock options as part of an annual equity compensation grant.

Director David Russell Gaugh was granted 8,143 restricted stock units and 17,365 stock options by Amphastar Pharmaceuticals.

Director Gayle Deflin acquired 8,143 restricted stock units and 17,365 stock options as part of an annual equity grant.

Amphastar Pharmaceuticals EVP Liawatidewi Yakob disposed of 1,033 shares of common stock to cover tax liabilities from restricted stock unit vesting.

Amphastar Pharmaceuticals Senior EVP Zhou Rong filed a Form 4 disclosing a future disposition of 1,225 common shares on March 15, 2026, to cover tax liabilities from RSU vesting.

Amphastar Pharmaceuticals' CFO, William J. Peters, reported a planned disposal of 1,973 shares of common stock on March 15, 2026, to cover tax liabilities from restricted stock unit vesting.

Amphastar Pharmaceuticals' CEO and COO withheld a total of 12,692 shares of common stock to cover tax liabilities related to restricted stock unit vesting.

Amphastar Pharmaceuticals' CFO, EVP & Treasurer, William J. Peters, reported the acquisition of restricted stock units and stock options, alongside a tax-related disposition of shares.

Amphastar Pharmaceuticals' Senior EVP, Production Center, Zhou Rong, reported a disposition of 1,124 common shares to cover tax liabilities from restricted stock unit vesting.

Amphastar Pharmaceuticals executive Liawatidewi Yakob reported a routine transaction involving the withholding of 965 shares for tax liability related to restricted stock units.

Amphastar Pharmaceuticals' CFO, William J. Peters, reported the disposition of 1,744 common shares to cover tax obligations related to restricted stock unit vesting.

Amphastar Pharmaceuticals' Senior EVP, Production Center, Zhou Rong, exercised stock options and immediately sold an equal number of shares for a profit.

Amphastar Pharmaceuticals Director Floyd F. Petersen reported scheduled sales of 4,163 shares of common stock under a Rule 10b5-1 plan.

Amphastar Pharmaceuticals Director Richard K. Prins exercised stock options and subsequently sold 4,179 shares of common stock on November 25, 2025.

Amphastar Pharmaceuticals Director Floyd F. Petersen exercised stock options and subsequently sold 16,679 shares of common stock.

Amphastar Pharmaceuticals Director Floyd F. Petersen sold 500 shares of common stock for a weighted average price of $25.2662 per share under a pre-arranged trading plan.

Amphastar Pharmaceuticals Director Floyd F. Petersen sold 500 shares of common stock for approximately $27.20 per share, executed under a pre-arranged 10b5-1 trading plan.

Amphastar Pharmaceuticals Director Floyd F. Petersen sold 500 shares of common stock for $30.9833 per share as part of a pre-arranged trading plan.

Amphastar Pharmaceuticals Director Floyd F. Petersen sold 500 shares of common stock for $20.8315 per share under a pre-arranged trading plan.

Amphastar Pharmaceuticals Director David Russell Gaugh was granted 6,304 restricted stock units and options to purchase 13,987 shares of common stock as part of his compensation.

A director at Amphastar Pharmaceuticals, Floyd F. Petersen, sold 500 shares of common stock for approximately $23.47 per share as part of a pre-established Rule 10b5-1 trading plan.

Amphastar Pharmaceuticals' CEO and COO, Jack Y. Zhang and Mary Z. Luo, respectively, exercised employee stock options to acquire 200,000 shares of common stock at $13.03 per share on June 13, 2025.

Amphastar Pharmaceuticals Director Howard Lee reported the acquisition of restricted stock units and stock options, alongside a disposition of shares for tax withholding purposes, as detailed in a recent SEC Form 4 filing.

Amphastar Pharmaceuticals, Inc. Director Gayle Deflin was granted 5,122 restricted stock units and options to purchase 11,402 shares of common stock, aligning her interests with shareholders.